October 6th 2025, 8:00pm
In EGFR-mutated non-small cell lung cancer Tagrisso with pemetrexed and chemotherapy was associated with an improvement in survival.
October 1st 2025, 1:00pm
Dr. Mary B. Beasley discusses evolving role of pathologists in lung cancer care, highlighting how emerging technologies may shape the future of the field.
September 26th 2025, 8:00pm
Ibtrozi may become the new standard for ROS1-mutated lung cancer, with phase 2 data showing safer, longer-lasting benefits for patients.
September 25th 2025, 8:00pm
Dr. Jacob A. Sands shares how patients with lung cancer can interpret clinical trial results and how these findings translate to treatment decisions.
September 16th 2025, 8:00pm
Dr. Joshua K. Sabari sat down with Terri Conneran at the 2025 World Conference on Lung Cancer for a conversation on the importance of biomarker testing.
September 15th 2025, 1:00pm
Dr. Joshua Sabari spoke with advocate Chris Conneran on his journey from caregiver to champion for KRAS-mutant cancer patients and families.
September 14th 2025, 2:00pm
Lutathera demonstrated antitumor activity in patients with metastatic bronchopulmonary neuroendocrine tumors.
September 13th 2025, 6:00pm
For patients with MET exon 14-altered NSCLC, Tepmetko was associated with frequent side effects, although the safety profile is considered manageable.
September 12th 2025, 8:00pm
Dr. Josh Sabari and Max Doppelt explore challenges in trial enrollment and the potential of emerging therapies to offer hope for patients diagnosed today.
September 12th 2025, 3:00pm
For patients with advanced non-small cell lung cancer who progressed on two or more prior regimens, THIO with Libtayo elicited positive responses.
Understanding Sarcoma: Types, Treatment and Living Well
Finding Hope Amidst a Lung Cancer Diagnosis
Navigating My Breast Cancer Treatment Decisions at 39
Survivorship and the Power of Community in Breast Cancer Awareness